3 recruiting, 2 active not recruiting, 2 completed. 7 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 3, Active not recruiting 2, Completed 2 |
| Phase 3 | 4 | Active not recruiting 2, Recruiting 2 |
| Phase 1 | 2 | Completed 2 |
Follow EyeBiotech Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-04-15 | 2026-08-06 |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-03-27 | 2026-10-02 |
| A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO Remigromig, Aflibercept 2.0 mg - Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO) | Phase 2 | Recruiting | EyeBiotech Ltd. | 160 | 2025-09-12 | 2026-10-20 |
| A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME Remigromig, Ranibizumab - Diabetic Macular Edema (DME) | Phase 2 / Phase 3 | Active not recruiting | EyeBiotech Ltd. | 1054 | 2025-04-16 | 2026-10-15 |
| A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration EYE201 - Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD) | Phase 1 / Phase 2 | Completed | EyeBiotech Ltd. | 38 | 2024-11-12 | 2026-08-24 |
| A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME Ranibizumab, Remigromig - Diabetic Macular Edema (DME) | Phase 2 / Phase 3 | Active not recruiting | EyeBiotech Ltd. | 984 | 2024-08-07 | 2026-10-14 |
| A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) EYE103 - Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME) | Phase 1 / Phase 2 | Completed | EyeBiotech Ltd. | 33 | 2023-06-12 | 2026-09-29 |
Macular Degeneration (3) · Choroidal Neovascularization (2) · Retinal Vein Occlusion (2) · Wet Macular Degeneration (2)
aflibercept (3) · Ranibizumab (2)
United States (7) · Puerto Rico (5) · Argentina (4) · Colombia (3) · Spain (3) · United Kingdom (3) · Australia (2) · Brazil (2) · Czechia (2) · France (2) · Germany (2) · Hungary (2) · Israel (2) · Italy (2) · Latvia (2)
2025 (1)